Elghawy O, Barsouk A, Sussman JH, Bleiberg BA, Reed-Guy L, D'Avella C, Singh A, Ciunci C, Robinson K, Kosteva J, Langer C, Cohen RB, Aggarwal C, Marmarelis M, Sun L. Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC , JTO Clin Res Rep, 6(9): 2025,100851

Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C. Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy , Clin Lung Cancer, 26(2): 2025,158-163.e2.

Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen RB, Robinson KW, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ, Sun L, Aggarwal C, Langer CJ, Yegya-Raman N. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation , Clin Lung Cancer, 25(3): 2024,e161-e171.

Cantor DJ, Davis C, Ciunci C, Aggarwal C, Evans T, Cohen RB, Bauml JM, Langer CJ. Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC , JTO Clin Res Rep, 5(6): 2024,100667

Ugarte S, D'Avella C, Gabriel P, Ciunci C, Roy M, Schwartz A, Boyk K, Walker S, Tindall J, Dougherty D The cancer diagnostic clinic: A rapid access clinic to improve outcomes for patients with a suspected cancer diagnosis. , American Society of Clinical Oncology Quality Care Symposium, San Francisco, CA.: 2024

Friedes C, Yegya-Raman N, Zhang S, Iocolano M, Cohen RB, Aggarwal C, Thompson JC, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, Singh AP, D'Avella C, Davis CW, Langer CJ, Feigenberg SJ. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression , Clin Lung Cancer, 25(1): 2024,50-60.e6.

Davis D, Jarrar S, Ciunci C Synchronous Primary Lung Cancers Containing Discrete Driver Mutations in a Never-Smoker: Case Report , Case Reports Oncology, 16(1): 2023,1384-1389

Tompkins WP, Hwang WT, Yang YX, Singh A, Ciunci C, D'Avella C, Aggarwal C, Cohen RB, Langer CJ, Mamtani R, Marmarelis ME. Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens , Clin Lung Cancer, 24(6): 2023,558-562.e2.

Yegya-Raman N, Berman AT, Ciunci CA, Friedes C, Berlin E, Iocolano M, Wang X, Lai C, Levin WP, Cengel KA, O'Reilly SE, Cohen RB, Aggarwal C, Marmarelis ME, Singh AP, Sun L, Bradley JD, Plastaras JP, Simone CB 2nd, Langer CJ, Feigenberg SJ. Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer , Int J Radiat Oncol Biol Phys, 119(23): 2023,56-65

Yegya-Raman N, Friedes C, Sun L, Iocolano M, Kim KN, Doucette A, Cohen RB, Robinson KW, Levin WP, Cengel KA, Lally B, Agarwal M, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Aggarwal C, Berman AT, Langer CJ, Feigenberg SJ. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System , Clin Lung Cancer, 24(5): 2023,474-482.